Business Description
Marker Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US57055L2060
Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.68 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 34.2 | |||||
| 3-Year EPS without NRI Growth Rate | 36.1 | |||||
| 3-Year FCF Growth Rate | 33.1 | |||||
| 3-Year Book Growth Rate | -33.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.05 | |||||
| 9-Day RSI | 43.38 | |||||
| 14-Day RSI | 45.59 | |||||
| 6-1 Month Momentum % | 4.6 | |||||
| 12-1 Month Momentum % | 29.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.15 | |||||
| Quick Ratio | 3.15 | |||||
| Cash Ratio | 2.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.6 | |||||
| Shareholder Yield % | -0.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -81.21 | |||||
| ROA % | -66.15 | |||||
| ROIC % | -1257.09 | |||||
| ROCE % | -85.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.19 | |||||
| Price-to-Tangible-Book | 4.14 | |||||
| EV-to-EBIT | -1.29 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Forward-Revenue | 0.56 | |||||
| EV-to-FCF | -1.53 | |||||
| Price-to-Net-Current-Asset-Value | 4.21 | |||||
| Price-to-Net-Cash | 5.61 | |||||
| Earnings Yield (Greenblatt) % | -77.52 | |||||
| FCF Yield % | -27.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Marker Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.007 | ||
| Beta | 0.34 | ||
| Volatility % | 82.38 | ||
| 14-Day RSI | 45.59 | ||
| 14-Day ATR (€) | 0.157414 | ||
| 20-Day SMA (€) | 3.102 | ||
| 12-1 Month Momentum % | 29.35 | ||
| 52-Week Range (€) | 2.12 - 5.3 | ||
| Shares Outstanding (Mil) | 8.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Marker Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Marker Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Marker Therapeutics Inc Frequently Asked Questions
What is Marker Therapeutics Inc(FRA:GX1)'s stock price today?
The current price of FRA:GX1 is €2.86. The 52 week high of FRA:GX1 is €5.30 and 52 week low is €2.12.
When is next earnings date of Marker Therapeutics Inc(FRA:GX1)?
The next earnings date of Marker Therapeutics Inc(FRA:GX1) is 2025-03-25 Est..
Does Marker Therapeutics Inc(FRA:GX1) pay dividends? If so, how much?
Marker Therapeutics Inc(FRA:GX1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers